Table 1.
Baseline characteristics of the included trials.
| Study | Country | Population | Sample size (% female) |
Intervention group | Sample size [intervention group] (% female) |
Mean age (years) ± SD [intervention group] |
Control group | Sample size [control group] (% female) | Mean age (years) ± SD [control group] |
Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| Wang et al. (2013)27 | China | Severe acute pancreatitis | 123 (49.6) | Ulinastatin + octreotide | 62 (50.0) | 41.8 ± 13.9 | Somatostatin | 61 (49.2) | 42.6 ± 12.6 | Mortality; MODS |
| Tu et al. (2014)28 | China | Acute pancreatitis | 110 (47.3) | Ulinastatin + octreotide | 55 (45.5) | 37.3 ± 6.1 | Octreotide | 55 (49.1) | 38.7 ± 5.8 | LOH; SR; APR |
| Guo et al. (2015)13 | China | Severe acute pancreatitis | 120 (46.7) | Ulinastatin + octreotide | 60 (48.3) | 46.6 ± 4.1 | Octreotide | 60 (45.0) | 46.3 ± 4.3 | Mortality; LOH; MODS; ARDS AKI; shock; SR; APR |
| Wang et al. (2016)14 | China | Severe acute pancreatitis | 246 (48.8) | Ulinastatin + octreotide | 124 (49.2) | 40.8 ± 11.6 | Somatostatin | 122 (48.4) | 41.9 ± 12.8 | Mortality; LOH; MODS; SR; APR |
| Wang et al. (2017)30 | China | Moderateliy severe and severe acute pancreatitis | 42 (40.5) | Ulinastatin + octreotide | 21 (42.9) | 47.3 ± 11.1 | Somatostatin | 21 (38.1) | 48.6 ± 10.0 | ARDS; AKI; shock; APR |
| Yang et al. (2017)32 | China | Severe acute pancreatitis | 88 (39.8) | Ulinastatin + octreotide | 44 (40.9) | 42.1 ± 9.8 | Octreotide | 44 (38.6) | 43.2 ± 9.2 | N/A |
| Yang et al. (2018)15 | China | Severe acute pancreatitis | 94 (37.2) | Ulinastatin + octreotide | 46 (41.3) | 46.2 ± 10.6 | Octreotide | 48 (33.3) | 47.7 ± 11.8 | Mortality; LOH; ARDS; AKI; shock; SR; APR |
| Meng et al. (2019)31 | China | Acute pancreatitis | 108 (45.4) | Ulinastatin + octreotide | 54 (N/A) | N/A | Octreotide | 54 (N/A) | N/A | SR |
| Xu et al. (2019)29 | China | Severe acute pancreatitis | 106 (49.1) | Ulinastatin + octreotide | 53 (50.9) | 57.0 ± 6.9 | Somatostatin | 53 (47.2) | 57.5 ± 7.4 | LOH; SR |
SD, standard deviation; N/A, not reported; MODS, multiple organ dysfunction syndrome; LOH, length of hospital stay; SR, symptom reduction; APR, abdominal pain relief; ARDS, acute respiratory distress syndrome; AKI, acute kidney injury.